Wider Definition of Vaccine to Include Active and Passive Immunity
National Health Amendment (Passive Immunological Products) Bill 2026
House of Representatives
Senate
Assent
Introduced by: The Hon Mark Butler MP (ALP)
Links to official parliament websites
Effects of this bill
If this bill passes, it means that:
The Debate
What different members said when this bill was debated:
Rebecca White ALP
“I move: That this bill be now read a second time. I am pleased to introduce the National Health Amendment (Passive Immunological Products) Bill 2026. This bill expands the definition of vaccine in the National Health Act 1953 to enable new and emerging therapies to be listed on the National Immunisation Program.”
Ms PRICE
“I rise to speak on the National Health Amendment (Passive Immunological Products) Bill 2026. The opposition supports this bill as a sensible technical reform that improves affordable access to immunisation products for families who choose to access these products, particularly families wanting to protect their babies from respiratory syncytial virus, known as RSV.”
Dr RYAN
“I rise to commend the National Health Amendment (Passive Immunological Products) Bill 2026 to the House. Vaccines are a cornerstone of our public health system. They protect us against serious and preventable illnesses, reduce the burden on our hospital system, help manage our chronic disease load and lower our lifetime healthcare costs.”
Anthony Chisholm ALP
“I table a revised explanatory memorandum relating to the Veterans’ Affairs Legislation Amendment (Miscellaneous Measures No. 2) Bill 2026 and move: That these bills be now read a second time. I seek leave to have the second reading speeches incorporated in Hansard. Leave granted. The speech es read as follows— AUSTRALIAN SECURITY INTELLIGENCE ORGANISATION AMENDMENT BILL (NO.”